Objective: This study aimed to examine the correlation between BRAF status and computed tomography (CT) imaging characteristics in papillary thyroid carcinoma (PTC) and determine if suspicious CT imaging features could predict BRAF status.
Methods: This retrospective study included patients with pathologically confirmed PTC at the Department of Thyroid Surgery of Zhongshan Hospital, Xiamen University, between July 2020 and June 2022. We compared the clinicopathologic factors and CT findings of nodules with and without the mutation, and the multiple logistical regression test was used to determine independent parameters of the BRAF mutation.
Results: This study included 381 patients with PTC, among them, BRAF mutation was detected in 314 patients (82.4%). Multivariate logistic regression analysis showed that gender (OR = 0.542, 95% CI [0.296-0.993], = 0.047) and shape (OR = 0.510, 95% CI [0.275-0.944], = 0.032) were associated with BRAF mutation.
Conclusions: Compared to BRAF mutation-negative, BRAF-positive PTC lesions were more likely to be found in female patients and were characterized by irregular shape. However, the CT imaging finding is not enough to predict BRAF status, but an indication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10821721 | PMC |
| http://dx.doi.org/10.7717/peerj.16810 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.
Expert Opin Drug Saf
January 2025
Department of Obstetrics, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objectives: Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.
Methods: This study performed a retrospective analysis using real-world data extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Blood Adv
February 2025
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record-derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre-novel therapy era (Pre era; 2014-2018; n = 2998) or post-novel therapy era (Post era; 2019-2022; n = 2098).
View Article and Find Full Text PDFUse of Machine Learning to Assess the Management of Uncomplicated Urinary Tract Infection.
JAMA Netw Open
January 2025
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts.
Importance: Uncomplicated urinary tract infection (UTI) is a common indication for outpatient antimicrobial therapy. National guidelines for the management of uncomplicated UTI were published in 2011, but the extent to which they align with current practices, patient diversity, and pathogen biology, all of which have evolved greatly in the time since their publication, is not fully known.
Objective: To reevaluate the effectiveness and adverse event profile for first-line antibiotics, fluoroquinolones, and oral β-lactams for treating uncomplicated UTI in contemporary clinical practice.
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.
JAMA Netw Open
January 2025
Healthcare Transformation Institute, Department of Medical Ethics and Health Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Importance: Adherence to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is important for their effectiveness. Discontinuation and reinitiation patterns are not well understood.
Objective: To describe rates of and factors associated with discontinuation and subsequent reinitiation of GLP-1 RAs among adults with overweight or obesity.
Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease.
JAMA Netw Open
January 2025
Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Approximately one-third of patients with ERBB2 (formerly HER2 or HER2/neu)-positive (ERBB2+) metastatic breast cancer (MBC) develop brain metastasis. It is unclear whether patients with disease limited to the central nervous system (CNS) have different outcomes and causes of death compared with those with concomitant extracranial metastasis.
Objective: To assess overall survival (OS) and CNS-related mortality among patients with ERBB2+ breast cancer and a diagnosis of CNS disease by disease distribution (CNS only vs CNS plus extracranial metastasis).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!